<DOC>
	<DOCNO>NCT02025348</DOCNO>
	<brief_summary>This open-label , randomised , 4-way crossover study twelve healthy male volunteer . The study characterise performance IntelliCap® evaluate plasma concentration pharmacokinetic profile probe drug ( IMP ; metoprolol ) release IntelliCap® three different release profile plasma concentration pharmacokinetic profile probe drug single dose oral solution .</brief_summary>
	<brief_title>Explore Performance IntelliCap .</brief_title>
	<detailed_description />
	<mesh_term>Metoprolol</mesh_term>
	<criteria>Healthy male volunteer age 18 50 year age , inclusive . Subjects body weight least 50 kg 100 kg , inclusive . Subjects body mass index ( BMI ) 18 30 kg/m2 , inclusive . BMI = Body weight ( kg ) / [ Height ( ) ] 2 . Subjects suitable vein cannulation repeat venepuncture . Subjects must available complete study . Subjects must satisfy medical examiner fitness participate study . Subjects must provide write informed consent participate study . History clinically important disease disorder , opinion Investigator , may either put subject risk participation study , influence result subject 's ability participate study . Abnormal vital sign , 10 min supine rest , define follow : Systolic blood pressure &lt; 100 mmHg ≥ 140 mmHg . Diastolic blood pressure &lt; 50 mmHg ≥ 90 mmHg . Heart rate &lt; 50 &gt; 85 beat per minute . Any clinically important abnormality rhythm , conduction morphology rest ECG . History severe allergy/hypersensitivity ongoing clinically important allergy/ hypersensitivity judge Investigator known hypersensitivity metoprolol ( include betablockers ) component product . •Plasma donation within one month screen blood donation/blood loss great 500 mL three ( 3 ) month prior screen . Receipt new chemical entity ( define compound approve marketing ) participation clinical study include drug treatment within least three ( 3 ) month first administration study treatment study . The period exclusion begin three month final dose . Note : subject consent screen , randomise study previous phase I study , exclude . Previous randomisation treatment present study . Involvement CRO/third party contractor AZ employee close relative regardless role . Judgement Investigator subject participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction requirement . Subjects communicate reliably Investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>